Evidence map›Paper›PMID 36034444›Full record

ArticleFrontiers in endocrinology2022

Genetics: Is LADA just late onset type 1 diabetes?

M Hernández, Y Nóvoa-Medina, R Faner, E Palou, A Esquerda, E Castelblanco, A M Wägner, D Mauricio

Open access · goldAbstract read
In one paragraph

Article in Frontiers in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

M HernándezDepartment of Endocrinology and Nutrition, University Hospital Arnau de Vilanova, Lleida, Spain.
Y Nóvoa-MedinaDepartment of Pediatrics, Complejo Hospitalario Universitario Insular Materno-Infantil, Las Palmas de Gran Canaria, Spain.
R FanerHistocompatibility and Immunogenetics Laboratory, Blood and Tissue Bank, Barcelona, Spain.
E PalouHistocompatibility and Immunogenetics Laboratory, Blood and Tissue Bank, Barcelona, Spain.
A EsquerdaDepartment of Laboratory Medicine, University Hospital Arnau de Vilanova, Lleida, Spain.
E CastelblancoDiabetis en Atenció Primària - Catalunya (DAP-Cat) Group, Unitat de Suport a la Recerca Barcelona, Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina, Barcelona, Spain.
A M WägnerResearch Institute in Biomedical and Health Sciences (IUIBS), University of Las Palmas de Gran Canaria (ULPGC), Las Palmas de Gran Canaria, Spain.
D MauricioDepartment of Endocrinology, Hospital de la Santa Creu i Sant Pau & Institut d'Investigació Biomèdica (IIB) Sant Pau, Barcelona, Spain.
Banc de Sang i Teixits · ESHospital Universitari Arnau de Vilanova · ESUniversidad de Las Palmas de Gran Canaria · ESCentro de Investigación Biomédica en Red · ESWashington University in St. Louis · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: There is a controversy regarding Latent Autoimmune Diabetes in Adults (LADA) classification and whether it should be considered a slowly progressing form of type 1 (T1) diabetes (DM) or a distinct type of DM altogether. Methods: This cross-sectional study assessed major genes associated with T1DM (class II Results: A total of 578 participants were included: 248 with T1DM (70 diagnosed after the age of 30), 256 with T2DM and 74 with LADA. High risk HLA alleles were significantly more frequent in LADA than in T2DM, whereas the opposite was true for protective alleles. We found a lower frequency of the high-risk DRB1*04-DQB1*03:02-DQA1*03:01 haplotype in LADA (21.1%) than in the overall T1DM (34.7%) (p<0.05), whereas no differences were found between these groups for DRB1*03-DQB1*02:01-DQA1*05:01 or for protective alleles. Only 12% the overall T1DM group had no risk alleles vs 30% of LADA (p<0.0005). However, HLA allele distribution was similar in LADA and T1DM diagnosed after the age of 30. A total of 506 individuals (195 with T1DM [21 diagnosed after age 30] 253 with T2DM and 58 with LADA) were genotyped for the Conclusion: In this relatively small cross-sectional study, the genetic profile of subjects with LADA showed a similar T1DM-related risk allele distribution as in participants with T1DM diagnosed after the age of 30, but fewer risk alleles than those diagnosed before 30. Differences were present for HLA, as well as

Indexed as

Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2Latent Autoimmune Diabetes in AdultsAdultAge of OnsetCross-Sectional StudiesGenetic Predisposition to DiseaseHumansProtein Tyrosine Phosphatase, Non-Receptor Type 22Protein Tyrosine Phosphatase, Non-Receptor Type 22PTPN22 protein, humanage of onsetgeneticsHLA class IIINSLADA (latent autoimmune diabetes in adults)PTPN22Type 1 diabetes mellitus

Identifiers

PMID36034444
PMCPMC9404871
OpenAlexW4291018396

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.